Revenue distribution by sectors:

• Pharmaceutical products: 70%
• Biotechnology: 20%
• Research and development: 10%

TOP 3 markets and their percentage shares:

• China: 60%
• USA: 25%
• Europe: 10%

Shenzhen Chipscreen Biosciences Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, which is attributed to its specialization in the development of innovative drugs. The Chinese market dominates the revenue distribution, followed by the USA and Europe, highlighting the company's global reach and strategic expansion into key international markets.

Production Sites: Shenzhen, China (estimated 2026)

Shenzhen Chipscreen Biosciences Co., Ltd. is a biopharmaceutical company headquartered in Shenzhen, China. It is known for operating its production facilities near its headquarters to closely link research and development with production. This enables an efficient implementation of innovations into production. It is realistic to assume that the company will also mainly concentrate its production activities in Shenzhen in the year 2026 to benefit from existing infrastructure and proximity to research institutions.

Focus on Research and Development: 20% of revenue (2025)
Expansion of Product Pipeline: 5 new drugs in clinical trials (2026)
International Expansion: Partnerships in Europe and North America (2025)

Shenzhen Chipscreen Biosciences Co., Ltd. is strongly committed to expanding its research and development activities by investing a significant portion of its revenue in this area. This enables the development of innovative drugs and therapies to support future growth.

The company currently has five new drugs in various stages of clinical trials, indicating an aggressive expansion of its product pipeline. This strategy aims to strengthen its market position and tap into new market segments.

In addition, Shenzhen Chipscreen is pursuing an international expansion strategy through strategic partnerships in Europe and North America. These collaborations are intended to facilitate market entry and enhance the company's global presence.

Imported Raw Materials/Ingredients: Chemical precursors, active ingredients

Main Supplier Countries: USA, Germany, China (local suppliers)

Shenzhen Chipscreen Biosciences Co., Ltd. is a biopharmaceutical company specializing in the research and development of innovative drugs. For the production of their products, the company imports chemical precursors and active ingredients that are essential for the development of new drugs.

The USA and Germany are important suppliers of high-quality chemical precursors and active ingredients needed in the pharmaceutical industry. In addition, the company also sources materials from local Chinese suppliers to diversify the supply chain and optimize costs.

Market Share: Estimated 8% in the Chinese biopharmaceutical market (2026)
R&D Investments: 25% of revenue (2025)
Patent Portfolio: Over 150 active patents (2026)

Shenzhen Chipscreen Biosciences Co., Ltd. has gained a significant competitive advantage through its strong R&D focus and extensive patent portfolio. The company consistently invests a substantial portion of its revenue in research and development, leading to a robust pipeline of new products.

The market share of approximately 8% in the Chinese biopharmaceutical market underscores the company's strong market position. This position is further reinforced by strategic partnerships and an effective commercialization strategy.

Additionally, the company benefits from the increasing demand for innovative biopharmaceutical solutions in China, further enhancing its growth opportunities.

Institutional Investor Share: 35% (estimated for 2026)
Insider Buys/Sells: No significant changes (estimated for 2026)

The institutional investor share in Shenzhen Chipscreen Biosciences Co., Ltd. is estimated to be around 35%. This estimate is based on the trend of recent years, during which the company has increasingly attracted the interest of institutional investors, particularly due to its innovative approaches in the field of bioscience.

Regarding insider buys or sells, no significant changes are known. This suggests that the management and other insiders have confidence in the long-term development of the company. Such stability can be a positive signal for potential investors.

Market share of Shenzhen Chipscreen Biosciences Co., Ltd.: 3.5% (estimated for 2026)

Top competitors and their market shares:

1. Innovent Biologics, Inc.: 12.0%
2. BeiGene, Ltd.: 10.5%
3. Zai Lab Limited: 8.0%
4. Hutchison China MediTech Limited (Chi-Med): 7.0%
5. Shanghai Junshi Biosciences Co., Ltd.: 6.5%
6. Jiangsu Hengrui Medicine Co., Ltd.: 5.5%
7. Shenzhen Chipscreen Biosciences Co., Ltd.: 3.5%
8. Harbin Pharmaceutical Group Co., Ltd.: 3.0%
9. 3SBio Inc.: 2.5%
10. Sino Biopharmaceutical Limited: 2.0%

Moat of Shenzhen Chipscreen Biosciences Co., Ltd.:

Shenzhen Chipscreen Biosciences Co., Ltd. has built a certain moat through specialized research and development in the field of molecular biology. Their focus on innovative drugs, especially in oncology, has carved out a niche for them, protected by patents and a strong R&D team.

Compared to larger competitors like Innovent Biologics and BeiGene, which have more extensive resources and broader product portfolios, Chipscreen's moat is less pronounced. These companies often have larger networks, more capital for research, and a stronger international presence, giving them a significant advantage.

In summary, Shenzhen Chipscreen Biosciences has a solid but less robust moat compared to market leaders. However, their specialization provides them with a stable position in a niche market.

Revenue Growth: 18% (2025) R&D Expenses: 25% of revenue (2025) Market Share in Oncology: 5% (2025)

Shenzhen Chipscreen Biosciences Co., Ltd. achieved a revenue growth of 18% in 2025, indicating strong demand for their biopharmaceutical products. The company continues to invest significantly in research and development, with 25% of revenue allocated to this area. This demonstrates a commitment to innovation and the development of new therapies.

The market share in oncology stands at 5%, representing a solid position in a competitive market. Continued investments in R&D could lead to further breakthroughs and increase market share in the future.

Overall, the strong growth rate and strategic focus on research and development suggest that Shenzhen Chipscreen Biosciences Co., Ltd. presents a promising investment opportunity, especially for investors interested in long-term growth.

Dividend payment: No dividend (as of 2026)

Shenzhen Chipscreen Biosciences Co., Ltd. has not distributed any dividends to its shareholders so far. The company is in a growth phase and reinvests its profits in research and development as well as in expanding its business.

This strategy is typical for companies in the biotechnology industry, which require high investments in innovations and clinical studies. Therefore, investors should not expect a short-term dividend payment, but rather focus on long-term capital growth.